Jon E. Stek

2.1k total citations
49 papers, 1.5k citations indexed

About

Jon E. Stek is a scholar working on Epidemiology, Infectious Diseases and Microbiology. According to data from OpenAlex, Jon E. Stek has authored 49 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 42 papers in Epidemiology, 14 papers in Infectious Diseases and 13 papers in Microbiology. Recurrent topics in Jon E. Stek's work include Herpesvirus Infections and Treatments (21 papers), Pneumonia and Respiratory Infections (14 papers) and Bacterial Infections and Vaccines (13 papers). Jon E. Stek is often cited by papers focused on Herpesvirus Infections and Treatments (21 papers), Pneumonia and Respiratory Infections (14 papers) and Bacterial Infections and Vaccines (13 papers). Jon E. Stek collaborates with scholars based in United States, Canada and Israel. Jon E. Stek's co-authors include Janie Parrino, Paula W. Annunziato, Myron J. Levin, Yanli Zhao, Ivan S. F. Chan, Timo Vesikari, Xiaoming Li, Jin Xu, Robert F. Betts and Shelly McNeil and has published in prestigious journals such as Blood, PEDIATRICS and Clinical Infectious Diseases.

In The Last Decade

Jon E. Stek

49 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jon E. Stek United States	23	1.2k	321	286	228	200	49	1.5k
Lily Yin Weckx Brazil	15	1.1k 1.0×	353 1.1×	216 0.8×	183 0.8×	126 0.6×	53	1.6k
Himal Lal Belgium	14	1.3k 1.1×	215 0.7×	376 1.3×	265 1.2×	60 0.3×	23	1.6k
Olivier Godeaux Belgium	10	1.1k 0.9×	245 0.8×	234 0.8×	166 0.7×	40 0.2×	20	1.4k
Lidia Oostvogels Belgium	21	733 0.6×	353 1.1×	225 0.8×	195 0.9×	27 0.1×	40	1.2k
Karin Galil United States	16	1.5k 1.3×	209 0.7×	440 1.5×	187 0.8×	108 0.5×	17	1.7k
Allen Izu United States	23	1.1k 1.0×	322 1.0×	54 0.2×	289 1.3×	205 1.0×	37	2.0k
R. Berger Switzerland	20	748 0.6×	213 0.7×	160 0.6×	131 0.6×	73 0.4×	44	1.1k
Miriam Wiese‐Posselt Germany	19	581 0.5×	464 1.4×	257 0.9×	124 0.5×	63 0.3×	45	1.1k
Stephen R. Preblud United States	20	1.2k 1.1×	396 1.2×	150 0.5×	128 0.6×	110 0.6×	34	1.6k
J. W. Gnann United States	16	984 0.8×	326 1.0×	189 0.7×	561 2.5×	28 0.1×	21	1.5k

Countries citing papers authored by Jon E. Stek

Since Specialization

Citations

This map shows the geographic impact of Jon E. Stek's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jon E. Stek with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jon E. Stek more than expected).

Fields of papers citing papers by Jon E. Stek

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jon E. Stek. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jon E. Stek. The network helps show where Jon E. Stek may publish in the future.

Co-authorship network of co-authors of Jon E. Stek

This figure shows the co-authorship network connecting the top 25 collaborators of Jon E. Stek. A scholar is included among the top collaborators of Jon E. Stek based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jon E. Stek. Jon E. Stek is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Buchwald, Ulrike K., Charles P. Andrews, John Ervin, et al.. (2021). Sequential administration of Prevnar 13™ and PNEUMOVAX™ 23 in healthy participants 50 years of age and older. Human Vaccines & Immunotherapeutics. 17(8). 2678–2690. 10 indexed citations

Wilck, Marissa B., Zemin Xu, Jon E. Stek, & Andrew W. Lee. (2020). Safety and immunogenicity of a fully-liquid DTaP-IPV-Hib-HepB vaccine (Vaxelis™) in premature infants. Human Vaccines & Immunotherapeutics. 17(1). 191–196. 8 indexed citations

Acosta, Camilo J., Stephanie O. Klopfer, Barbara J. Kuter, et al.. (2018). Safety and immunogenicity of VAQTA® in children 12-to-23 months of age with and without administration of other US pediatric vaccines. Human Vaccines & Immunotherapeutics. 15(2). 426–432. 4 indexed citations

Andrews, Charles P., Steven Folkerth, Richard Rupp, et al.. (2018). Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naïve adults ≥50 years of age. Vaccine. 36(45). 6875–6882. 33 indexed citations

Xu, Jin, et al.. (2018). Integrated Safety Profile of a New Approved, Fully Liquid DTaP5-HB-IPV-Hib Vaccine. The Pediatric Infectious Disease Journal. 38(4). 439–443. 7 indexed citations

Martinón‐Torres, Federico, David Greenberg, Meera Varman, et al.. (2017). Safety, Tolerability and Immunogenicity of Pentavalent Rotavirus Vaccine Manufactured by a Modified Process. The Pediatric Infectious Disease Journal. 36(4). 417–422. 5 indexed citations

Parrino, Janie, Shelly McNeil, Steven J. Lawrence, et al.. (2017). Safety and immunogenicity of inactivated varicella-zoster virus vaccine in adults with hematologic malignancies receiving treatment with anti-CD20 monoclonal antibodies. Vaccine. 35(14). 1764–1769. 33 indexed citations

Levin, Myron J., et al.. (2017). Immunogenicity and safety of zoster vaccine live administered with quadrivalent influenza virus vaccine. Vaccine. 36(1). 179–185. 19 indexed citations

Marshall, Gary S., Shelly Senders, Darcy A. Hille, et al.. (2016). A double blind, randomized, active controlled study to assess the safety, tolerability and immunogenicity of measles, mumps rubella, and varicella vaccine (MMRV) manufactured using an alternative process. Human Vaccines & Immunotherapeutics. 12(8). 2188–2196. 3 indexed citations

10.

Ciprero, Karen L., Rocio D. Marchese, Patrick O. Richard, et al.. (2016). Vaccination of adults with 23-valent pneumococcal polysaccharide vaccine induces robust antibody responses against pneumococcal serotypes associated with serious clinical outcomes. Human Vaccines & Immunotherapeutics. 12(8). 2135–2141. 3 indexed citations

11.

Silfverdal, Sven‐Arne, Giancarlo Icardi, Timo Vesikari, et al.. (2016). A Phase III randomized, double-blind, clinical trial of an investigational hexavalent vaccine given at 2, 4, and 11–12 months. Vaccine. 34(33). 3810–3816. 32 indexed citations

12.

Vesikari, Timo, Thomas Becker, André Vertruyen, et al.. (2016). A Phase III Randomized, Double-blind, Clinical Trial of an Investigational Hexavalent Vaccine Given at Two, Three, Four and Twelve Months. The Pediatric Infectious Disease Journal. 36(2). 209–215. 22 indexed citations

13.

Ciprero, Karen L., Н. И. Брико, Tulin Shekar, et al.. (2016). Safety and immunogenicity of a single dose 23-valent pneumococcal polysaccharide vaccine in Russian subjects. Human Vaccines & Immunotherapeutics. 12(8). 2142–2147. 7 indexed citations

14.

Mullane, Kathleen M., Drew J. Winston, M. S. Wertheim, et al.. (2013). Safety and Immunogenicity of Heat-Treated Zoster Vaccine (ZVHT) in Immunocompromised Adults. The Journal of Infectious Diseases. 208(9). 1375–1385. 59 indexed citations

15.

Levin, Myron J., Kenneth E. Schmader, John W. Gnann, et al.. (2013). Varicella-Zoster Virus–Specific Antibody Responses in 50–59-Year-Old Recipients of Zoster Vaccine. The Journal of Infectious Diseases. 208(9). 1386–1390. 29 indexed citations

16.

Yetman, Robert J., Jon E. Stek, Stephanie O. Klopfer, et al.. (2013). Concomitant administration of hepatitis A vaccine with measles/mumps/rubella/varicella and pneumococcal vaccines in healthy 12- to 23-month-old children. Human Vaccines & Immunotherapeutics. 9(8). 1691–1697. 17 indexed citations

17.

Lange, Joep M. A., Stephen K. Tyring, Gregory A. Poland, et al.. (2011). Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults ≥60 years of age. Vaccine. 30(5). 904–910. 50 indexed citations

18.

Murray, Alexander V., Keith S. Reisinger, Boris Kerzner, et al.. (2011). Safety and tolerability of zoster vaccine in adults ≥60 years old. Human Vaccines. 7(11). 1130–1136. 32 indexed citations

19.

Sutradhar, Santosh, Katia Schlienger, Jon E. Stek, et al.. (2009). Comparison of the Levels of Immunogenicity and Safety of Zostavax in Adults 50 to 59 Years Old and in Adults 60 Years Old or Older. Clinical and Vaccine Immunology. 16(5). 646–652. 25 indexed citations

20.

Coffin, Susan, Colin D. Marchant, Mark Sawyer, et al.. (2006). Impact of Acute Rotavirus Gastroenteritis on Pediatric Outpatient Practices in the United States. The Pediatric Infectious Disease Journal. 25(7). 584–589. 46 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact